The PARADIGM-HF trial demonstrated superiority of sacubitril/valsartan (ARNI) over enalapril in heart failure with reduced ejection fraction. The primary endpoint of this trial was:

• A All-cause mortality at 5 years
• B Improvement in LVEF > 5% at 24 months
• C Reduction in NT-proBNP levels by 50%
• D Composite of cardiovascular death or first hospitalisation for worsening heart failure ✓

Explanation

PARADIGM-HF (NEJM 2014) demonstrated that sacubitril/valsartan reduced the primary composite endpoint of cardiovascular death or first hospitalisation for worsening HF by 20% compared to enalapril in HFrEF patients (LVEF ≤40%, NYHA II–IV). The trial was stopped early due to overwhelming benefit. This established ARNI as a cornerstone of HFrEF therapy.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.